Breakthrough drug designed to attack breast cancer that spreads to brain

This study is testing whether a new experimental drug called RO7771950 works better than the current standard treatment (tucatinib) for advanced HER2-positive breast cancer that has spread or is hard to treat. Both drugs are given with two other cancer medications (trastuzumab and capecitabine). The new drug is specially designed to cross into the brain, which could help patients whose cancer has spread there. The trial will enroll about 650 people whose cancer has progressed despite previous treatments.